<DOC>
	<DOCNO>NCT00004339</DOCNO>
	<brief_summary>OBJECTIVES : Evaluate safety efficacy ammonium tetrathiomolybdate alone compare trientine therapy initial treatment patient Wilson disease present neurologically .</brief_summary>
	<brief_title>Study Tetrathiomolybdate Patients With Wilson Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This double blind , randomize study . Patients randomize one two treatment arm . Arm I : Patients receive tetrathiomolybdate ( TM ) 3 time day meals 3 time day meal 8 week absence neurologic deterioration unacceptable toxicity . Arm II : Patients receive trientine therapy 8 week absence neurologic deterioration unacceptable toxicity . Additional therapy ( study ) : Patients TM group may receive maintenance zinc , trientine group may continue trientine switch zinc .</detailed_description>
	<mesh_term>Hepatolenticular Degeneration</mesh_term>
	<mesh_term>Tetrathiomolybdate</mesh_term>
	<mesh_term>Trientine</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Wilson disease present neurologic psychiatric symptom No concurrent seizure activity No white matter lesion brain magnetic resonance image Prior/Concurrent Therapy No 2 week prior therapy No penicillamine trientine longer 2 week Patient Characteristics Hepatic : No severe hepatic failure Other : No psychiatric medical contraindication protocol therapy Not pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>Wilson disease</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>rare disease</keyword>
</DOC>